IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Ballentine Partners LLC

Ballentine Partners LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 11.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,424 shares of the medical research company’s stock after purchasing an additional 150 shares during the period. Ballentine Partners LLC’s holdings in IQVIA were worth $360,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in IQV. Kestra Advisory Services LLC increased its holdings in shares of IQVIA by 39.1% in the 3rd quarter. Kestra Advisory Services LLC now owns 5,344 shares of the medical research company’s stock valued at $1,051,000 after acquiring an additional 1,502 shares during the last quarter. Mariner LLC lifted its holdings in shares of IQVIA by 9.0% in the 3rd quarter. Mariner LLC now owns 14,566 shares of the medical research company’s stock valued at $2,866,000 after buying an additional 1,197 shares during the period. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of IQVIA by 10.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,071 shares of the medical research company’s stock valued at $211,000 after buying an additional 97 shares during the period. Natixis Advisors L.P. lifted its holdings in shares of IQVIA by 7.9% in the 3rd quarter. Natixis Advisors L.P. now owns 150,441 shares of the medical research company’s stock valued at $29,599,000 after buying an additional 11,029 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of IQVIA by 18.1% in the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock valued at $68,000 after buying an additional 53 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $214.06 on Tuesday. The company has a market cap of $39.00 billion, a P/E ratio of 29.24, a P/E/G ratio of 1.97 and a beta of 1.54. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The business has a fifty day simple moving average of $225.23 and a 200-day simple moving average of $230.38.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Friday. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective for the company. Finally, Robert W. Baird reduced their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a report on Friday, May 3rd. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $258.40.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.